Inside the Lab Oncology, Precision medicine, Genetics and epigenetics, Biochemistry and molecular biology, Technology and innovation, Training and education

Oncomine Dx Target Test – an IVD NGS solution for every lab

contributed by Thermo Fisher Scientific | 02/20/2019

With the ongoing development of precision oncology and more and more biomarkers entering routine clinical testing, a true end-to-end IVD solution, consolidating everything into one streamlined workflow, is needed in more pathology laboratories. The Oncomine Dx Target Test, based on next-generation sequencing (NGS), is now available in Europe and offers just that – 46 gene targets, including biomarkers associated with approved and investigative targeted therapies, all from one test, in one workflow, and in four days. Among the biomarkers tested are not only EGFR,ALK,ROS1 and BRAF but also cMET, NTRK1/2/3, RET, ERBB2, and others, currently in clinical trials.

Email*

Choose a password

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

I want to stay up to date with the Infectious Diseases field I want to stay up to date with the Pathologist Educator field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.